Bausch + Lomb BLCO Vision Care — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bausch + Lomb's vision care — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bausch + Lomb's vision care — R&D?
- Bausch + Lomb (BLCO) reported vision care — R&D of $10M in Q1 2026.
- How has Bausch + Lomb's vision care — R&D changed year-over-year?
- Bausch + Lomb's vision care — R&D increased by 25.0% year-over-year, from $8M to $10M.
- What is the long-term trend for Bausch + Lomb's vision care — R&D?
- Over 3 years (2022 to 2025), Bausch + Lomb's vision care — R&D has grown at a -5.0% compound annual growth rate (CAGR), from $56M to $48M.
- What does vision care — R&D mean?
- Represents the investment in scientific research and product development aimed at creating new vision care solutions or improving existing ocular health products. This expenditure is critical for maintaining long-term innovation and competitive advantage in the vision care industry. High levels of investment indicate a commitment to future product pipelines and technological leadership.